01—Abstract
Summary
Summary of the 10-K filed February 23, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s 2023 Form 10-K highlights a significant transition from pandemic-driven COVID-19 vaccine sales to an endemic, seasonal commercial market.
This shift led to a substantial decrease in net product sales to $6.7 billiona in 2023, down from $18.4 billion in 2022. The company has taken steps to resize its manufacturing infrastructure and manage costs associated with this transition, incurring significant charges related to inventory write-downs and CMO wind-downs. Despite the revenue decline, Moderna continues to invest heavily in its robust mRNA platform and diverse pipeline, with 45 programs in development, nine of which are in late-stage.
Key near-term catalysts include the anticipated 2024 launch of its RSV vaccine, ongoing Phase 3 trials for its combination flu/COVID-19 vaccine, and progress in its personalized cancer therapy (INT) program with Merck. The company's financial results reflect this evolving landscape, with a reported net loss of $4.7 billionb for 2023, contrasting with a net income of $8.4 billion in 2022. This loss is attributed to lower COVID-19 vaccine sales and continued substantial investments in research and development.
Moderna ended 2023 with a strong cash position of $13.3 billionc, providing a cushion for ongoing pipeline development and operations, though future profitability remains contingent on successful product launches and market adoption beyond its COVID-19 franchise. Significant risks highlighted include the competitive pharmaceutical market, potential delays in clinical development and regulatory approvals, and manufacturing complexities of mRNA technologies.
02—Key points
Key Highlights
- Net product sales significantly declined to $6.7 billion in 2023 from $18.4 billion in 2022, driven by the transition of the COVID-19 vaccine market to an endemic phase and increased seasonality.
- The company reported a net loss of $4.7 billion for 2023, a substantial change from a net income of $8.4 billion in 2022, reflecting reduced sales and continued R&D investments.
- Moderna maintains a strong cash and investments position of $13.3 billion as of December 31, 2023, providing financial flexibility for pipeline development.
- The pipeline remains robust with 45 programs, including nine in late-stage development, with key advancements expected in 2024 for the RSV vaccine launch and combination flu/COVID-19 vaccine.
- Significant investments in R&D continue, with expenses increasing by 47% to $4.8 billion in 2023, driven by late-stage clinical trials across multiple vaccine and therapeutic candidates.
- The company incurred substantial charges in 2023 ($1.4 billion in Q3, $169 million in Q4) related to resizing its manufacturing infrastructure for the endemic COVID-19 market, including inventory write-downs and CMO wind-down costs.
- Moderna is actively pursuing strategic collaborations, notably with Merck for its individualized neoantigen therapy (INT) program, with Phase 3 trials ongoing and showing promising results.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2023, Moderna, Inc. lost $0.69.
- Revenue$6.85B100.0%
- Cost of revenue−$4.69B68.5%
- Gross profit$2.15B31.5%
- Operating costs−$6.39B93.4%
- Operating income−$4.24B61.9%
- Interest, other & tax−$475.0M6.9%
- Net income−$4.71B68.8%
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 23, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $6.85B$19.26B | −64.4% |
| Cost of Revenue | $4.69B$5.42B | −13.3% |
| Gross Profit | $2.15B$13.85B | −84.4% |
| R&D Expenses | $4.84B$3.29B | +47.0% |
| Operating Expenses | $11.09B$9.84B | +12.6% |
| Operating Income | -$4.24B$9.42B | −145.0% |
| Net Income | -$4.71B$8.36B | −156.4% |
| EPS (Basic) | $-12.33$21.26 | −158.0% |
| EPS (Diluted) | $-12.33$20.12 | −161.3% |
| Shares Outstanding (Basic) | 382.00M394.00M | −3.0% |
| Shares Outstanding (Diluted) | 382.00M416.00M | −8.2% |
05—Questions
Frequently Asked Questions
What is Moderna's outlook for COVID-19 vaccine sales in 2024?
Moderna anticipates that sales of its COVID-19 vaccine in 2024 will be lower than in 2023, reflecting the market's progression towards a seasonal, endemic commercial model. The company has resized its manufacturing footprint to align with this expected lower demand.
What are the key pipeline developments expected in 2024?
Moderna expects significant advancements in 2024, including the potential launch of its RSV vaccine (mRNA-1345) following expected regulatory approvals, continued progress in Phase 3 trials for its combination flu/COVID-19 vaccine (mRNA-1083), and the intention to file for regulatory approval for its seasonal flu vaccine candidate (mRNA-1010). Additionally, potential efficacy data from the Phase 3 CMV vaccine study (mRNA-1647) and advancement of rare disease programs (PA and MMA) into pivotal studies are anticipated.
How has the transition to an endemic COVID-19 market impacted Moderna's financials?
The transition has led to a substantial decrease in net product sales, a net loss for 2023 after profits in prior years, and significant charges related to resizing manufacturing operations and inventory adjustments. The company incurred $1.4 billion in charges in Q3 2023 and an additional $169 million in Q4 2023 for these restructuring efforts.
What is Moderna's strategy for future growth beyond COVID-19?
Moderna's strategy focuses on leveraging its mRNA platform across multiple modalities, including infectious disease vaccines (RSV, flu, latent viruses), oncology (individualized neoantigen therapy), rare diseases, and autoimmune diseases. The company aims to launch up to 15 new products over the next five years, supported by ongoing R&D investment and strategic collaborations.
06—Continue